Published July 2026 | 7 min read
It is one of the most common questions people ask before starting a GLP-1 medication: what happens if I stop? It is a fair question. These medications are effective, but they are not a short course of treatment you finish and walk away from. The research on this is unusually clear, and it is worth understanding before you start rather than after. Here is what the trials actually found when people came off treatment, why it happens, and what it means for building a plan that lasts.
GLP-1 medications such as semaglutide and tirzepatide mimic gut hormones your body naturally releases after you eat. They reduce appetite, slow how quickly your stomach empties, and make it easier to eat less without feeling deprived. [6] That effect is real, but it depends on the medication being present in your body. The medication is not retraining your appetite permanently or resetting your metabolism to a new baseline. It is actively holding appetite signals in a different place for as long as you take it. That single fact explains most of what follows.
Two trials were designed specifically to answer this question, and they agree.
In the STEP 4 trial, everyone took semaglutide for 20 weeks and then half were switched to a placebo. Over the following 48 weeks, the group that stayed on semaglutide lost another 7.9 percent of body weight. The group that switched to placebo gained 6.9 percent back. [1] That is a gap of nearly 15 percentage points between continuing and stopping, in the same people, under the same conditions.
SURMOUNT-4 ran the same design with tirzepatide. After 36 weeks of treatment, participants either continued or switched to placebo. Over the next 52 weeks the placebo group regained 14.0 percent of body weight, while those who continued lost a further 5.5 percent. [3] The clearest number in that trial may be this one: 89.5 percent of people who stayed on treatment held onto at least 80 percent of the weight they had lost, compared with 16.6 percent of those who stopped. [3]
| Continued treatment | Switched to placebo | |
|---|---|---|
| Semaglutide, weight change after switch | -7.9% | +6.9% |
| Tirzepatide, weight change after switch | -5.5% | +14.0% |
| Kept 80%+ of weight lost (tirzepatide) | 89.5% | 16.6% |
The trials above stopped measuring after about a year. One study followed people further. Participants from the original STEP 1 trial were tracked for a full year after coming off semaglutide with no medication at all. In that year they regained an average of 11.6 percentage points of body weight, roughly two-thirds of what they had lost. [2]
There is a second half to that finding that often gets left out. Even a year after stopping, those participants were still about 5.6 percent below their starting weight, compared with almost no net change in the placebo group. [2] So stopping does not erase everything. But it does undo most of it, and it tends to keep moving in that direction over time.
This is the part worth sitting with, because the instinct is to read weight regain as a failure of willpower. The trials suggest otherwise. When you lose a significant amount of weight, your body defends against it: appetite hormones shift, hunger signals get louder, and energy expenditure adjusts downward. That response is not unique to medication. It happens after weight loss from any method, and it is a large part of why keeping weight off has always been harder than losing it.
A GLP-1 works by counteracting those signals. Remove the medication and the underlying biology is still there, unchanged, doing what it has always done. The weight coming back is not evidence the medication failed. It is evidence the medication was working, and the condition it was treating did not go away.
The flip side of all this data is genuinely encouraging: the results hold as long as treatment does. In a two-year study, people on semaglutide were still about 15 percent below their starting weight at 104 weeks. [5] In SURMOUNT-4, people who continued tirzepatide kept losing through week 88, finishing at about 25 percent total weight reduction. [3]
Staying on treatment does not necessarily mean staying on the same dose forever. It means treating weight the way other chronic conditions are treated, with ongoing care and periodic adjustment rather than a fixed endpoint. What that looks like for you is a clinical decision, and it is one your provider should be making with you rather than one you make alone at the pharmacy counter.
If you are considering a GLP-1, the most useful thing you can do is decide up front that this is a long-term plan and not a sprint. Ask your provider what maintenance looks like before you start. Ask what happens if you need to pause, what the options are if cost or supply changes, and how the plan adapts once you reach your goal. The people who do best with these medications are generally the ones who treated the first prescription as the start of an ongoing relationship with their care team.
If you are already on a GLP-1 and thinking about stopping, do not stop on your own. Talk with a licensed provider first. There are real reasons someone might come off treatment, and there are ways to plan for it that give you a better chance of holding onto your progress than simply stopping cold.
